Drug Profile
Research programme: monoamine oxidase inhibitors - Sumitomo Pharma America
Alternative Names: SEP 230864Latest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Sumitomo Pharma America
- Class
- Mechanism of Action Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder; Mood disorders; Pain
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mood disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA